CoChat

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis

Open access

Abstract

Objectives: To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes. Design and setting: Systematic review and meta-analysis of randomised, controlled trials. Data sources: Literature searches were performed across PubMed, EMBASE, MEDLINE and Cochrane Central Register of Controlled Trials from 1966 to May 2016 to identify randomised, controlled trials with more than 1 year follow-up. Outcome measures: Relative risk (RR) with 95% CI was used to evaluate the association between pioglitazone and the risk of major adverse cardiovascular events (MACE: composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) and safety outcomes, after pooling data across trials in a fixed-effects model. Results: Nine trials with 12 026 participants were enrolled in the current meta-analysis. Pioglitazone therapy was associated with a lower risk of MACE in patients with pre-diabetes or insulin resistance (RR 0.77, 95% CI 0.64 to 0.93), and diabetes (RR 0.83, 95% CI 0.72 to 0.97). Risks of heart failure (RR 1.32; CI 1.14 to 1.54), bone fracture (RR 1.52, 95% CI 1.17 to 1.99), oedema (RR, 1.63; CI 1.52 to 1.75) and weight gain (RR 1.60; CI 1.50 to 1.72) increased in pioglitazone group. Conclusions: Pioglitazone was associated with reduced risk of MACE in people with insulin resistance, pre-diabetes and diabetes mellitus. However, the risks of heart failure, bone fracture, oedema and weight gain were increased.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2016-013927

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Separate and pooled relative risk and 95% CIs estimates for cardiovascular outcomes among patients with pre-diabetes or insulin resistance (pioglitazone vs control).
Figure 1 Separate and pooled relative risk and 95% CIs estimates for cardiovascular outcomes among patients with pre-diabetes or insulin resistance (pioglitazone vs control).CC BY-NC · PubMed Central
Figure 2 Trial sequential analysis for (A) MACE, (B) myocardial infarction, (C) stroke, among patients with pre-diabetes or insulin resistance. (A) A full blue cumulative Z-curve did not cross the required information size boundary but did cross boundary for benefit. (B) and (C) the required information size has not been reached and none of the boundaries for benefit, harm or futility has been crossed. MACE, major adverse cardiovascular events.
Figure 2 Trial sequential analysis for (A) MACE, (B) myocardial infarction, (C) stroke, among patients with pre-diabetes or insulin resistance. (A) A full blue cumulative Z-curve did not cross the required information size boundary but did cross boundary for benefit. (B) and (C) the required information size has not been reached and none of the boundaries for benefit, harm or futility has been crossed. MACE, major adverse cardiovascular events.CC BY-NC · PubMed Central
Figure 3 Separate and pooled relative risk and 95% CIs estimates for cardiovascular outcomes among patients with type 2 diabetes mellitus (pioglitazone vs control).
Figure 3 Separate and pooled relative risk and 95% CIs estimates for cardiovascular outcomes among patients with type 2 diabetes mellitus (pioglitazone vs control).CC BY-NC · PubMed Central
Figure 4 Trial sequential analysis for (A) MACE, (B) myocardial infarction, (C) stroke, among patients with diabetes mellitus. (A), (B) and (C): the required information size has not been reached and none of the boundaries for benefit, harm or futility has been crossed. MACE, major adverse cardiovascular events.
Figure 4 Trial sequential analysis for (A) MACE, (B) myocardial infarction, (C) stroke, among patients with diabetes mellitus. (A), (B) and (C): the required information size has not been reached and none of the boundaries for benefit, harm or futility has been crossed. MACE, major adverse cardiovascular events.CC BY-NC · PubMed Central
Figure 5 Separate and pooled relative risk and 95% CIs estimates for safety outcomes among all included trials (pioglitazone vs control).
Figure 5 Separate and pooled relative risk and 95% CIs estimates for safety outcomes among all included trials (pioglitazone vs control).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 215

Metadata

Authors
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B.
Affiliations
  • Jia-Yi Clinic, Taoyuan, Taiwan
  • University of California, Los Angeles (US)
  • Chang Gung University (TW)
  • Wan Fang Hospital (TW)
  • Medical University of South Carolina (US)
Corresponding author
Lee, Meng
Venue
BMJ Open
Publisher
BMJ
Published
2017-01
Volume
7
Issue
1
Pages
e013927
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2568525643
Cited by
198
References
44
Citations by year
2026: 11 · 2025: 15 · 2024: 18 · 2023: 20 · 2022: 29 · 2021: 21 · 2020: 24 · 2019: 27 · 2018: 18 · 2017: 14
FWCI
3.31
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
Ministry of Science and Technology (MOST104-2314-B-182-019 and MOST105-2628-B-182-008-)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
pioglitazone, insulin resistance, prediabetes, type 2 diabetes, major adverse cardiovascular events, heart failure, bone fractures, edema, weight gain, adverse drug reactions, thiazolidinediones
MeSH terms
Pioglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Edema, Humans, Hypoglycemic Agents, Insulin Resistance, Prediabetic State, Weight Gain, Randomized Controlled Trials as Topic, Thiazolidinediones, Fractures, Bone, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2016-013927
The paper
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017). Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2016-013927

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.